ANTITHROMBOTIC THERAPY IN PATIENTS WITH ATRIAL FIBRILLATION AND ACUTE CORONARY SYNDROME – PROBLEMS AND WAYS TO SOLVE

The article provides an overview of modern approaches to the combined prescription of antithrombotic drugs in patients with atrial fibrillation who have indications for taking oral anticoagulants when they develop acute coronary syndrome, requiring the prescription of parenteral anticoagulants and antiplatelet agents. These approaches are aimed at increasing the effectiveness of antithrombotic therapy while reducing the risk of developing hemorrhagic complications.

1. Klinicheskiy protokol diagnostiki i lecheniya infarkta miokarda, nestabil’noy stenokardii (utverzhden postanovleniyem Ministerstva zdravookhraneniya Respubliki Belarus’ ot 06.06.2017 № 59). str. 43. [Clinical protocol of diagnosis and treatment of myocardial infarction, unstable angina (approved by the Ministry of Health of the Republic of Belarus dated 06.06.2017 № 59). p. 43]. Available at: http://minzdrav.gov.by/ru/static/spavochnoinfirm/protololy_lechenia/protok_2017

2. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC: endorsed by the European Stroke Organisation (ESO. // European Heart J. 2016; 37: 2893–2962.

3. 2017 ESC/EACTS Guidelines for the management of valvular heart disease // European Heart J. 2017; 38: 2739–279.

4. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation // Eur Heart J. 2018; 39(2):119-177

5. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) // European Heart J. 2021; 42 (5): 373–498.

6. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation // European Heart J. 2021; 42(14):1289-1367.

7. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation // Europace 2021; 23: 1612–1676.

8. 2023 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation // European Heart J. 2023; 44 (23): 3720-3826.

9. Camm A. J., Amarenco P., Haas S., Hess S., Kirchhof P., Kuhls S., van Eickels M., Turpie A. G. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation // European Heart J. 2016; 37: 1145–1153.

10. Cannon C. P., Bhatt D. L., Oldgren J., Lip G. Y. H., Ellis S. G., Kimura T., et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation // New England J. Medicine 2017; 377: 1513–1524 / https://doi.org/10.1056/NEJMoa1708454.

11. Connolly S. J., Ezekowitz M. D., Yusuf S., Reilly P. A., Wallentin L. Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. New England Journal of Medicine 2010; 363: 1875–1876.

12. Eikelboom J. W., Mehta S. R., Anand S. S., Xie C., Fox K. A., Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. // Circulation 2006; 114: 774–782.

13. Granger C. B., Alexander J. H., McMurray J. J., Lopes R. D., Hylek E. M., Hanna M., Al-Khalidi H. R., Ansell J., Atar D., Avezum A., Bahit M. C., Diaz R., Easton J. D., Ezekowitz J. A., Flaker G., Garcia D., Geraldes M., Gersh B. J., Golitsyn S., Goto S., Hermosillo A. G., Hohnloser S. H., Horowitz J., Mohan P., Jansky P., Lewis B. S., Lopez-Sendon J. L., Pais P., Parkhomenko A., Verheugt F. W., Zhu J., Wallentin L. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation // New England Journal of Medicine 2016; 365: 981–992.

14. Kikkert W. J., Delewi R., Ouweneel D. M., van Nes S. H., Vis M. M., Baan J. Jr., Koch K. T., Dangas G. D., Mehran R., de Winter R. J., Peters R. J., Piek J. J., Tijssen J. G., Henriques J. P. Prognostic value of access site and non-access site bleeding after percutaneous coronary intervention: a cohort study in ST-segment elevation myocardial infarction and comprehensive meta-analysis // JACC Cardiovascular Intervention 2014; 7: 622–630.

15. Lopes R. D., Subherwal S., Holmes D. N., Thomas L.,Wang T. Y., Rao S. V., Magnus Ohman E., Roe M. T., Peterson E. D., Alexander K. P. The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction // European Heart J. 2012; 33: 2044–2053.

16. Lopes R. D., Heizer G., Aronson R., Vora A. N., Massaro T., Mehran R., et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. // N Engl. J. Med. 2019; 380:1509–1524. / https://doi.org/10.1056/NEJMoa1817083.

17. Ruff C. T., Giugliano R. P., Braunwald E., Hoffman E. B., Deenadayalu N., Ezekowitz M. D., Camm A. J., Weitz J. I., Lewis B. S., Parkhomenko A., Yamashita T., Antman E. M. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955–962.